Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome
Avainsanat
Abstrakti
Kuvaus
Methodology: After a written informed consent obtained, women who are fitting the inclusion criteria will be randomly allocated using sealed, coded, opaque and sequentially numbered envelopes containing computer generated random numbers into either the study group or the control group. For the study group the enrolled women will receive 50 microgram misoprostol vaginally within 60 minutes before CS. For the control group mothers enrolled will receive nothing.
Observation and data collection: Cardiotocographic monitoring will be undertaken after maternal misoprostol administration to detect any evidence of uterine hyperstimulation and fetal distress.
Ritodrine IV will be used as a tocolytic agent in case of uterine tachysystole. 100 mg of ritodrine will be added to 500 ml of 0.5% dextrose, the solution will be administered as following:
5 drops / minute in the 1st 10 minutes. 10 drops / minute in the next 10 minutes then 15 drops / minute . The clinician should adjust the infusion rate so that the pulse rate doesn't exceed 120b/min and lung bases are free of crepitations.
The surgical and anesthetic teams will be in a state of complete readiness for the ECS from the time of maternal misoprostol administration after enrollment. Details on maternal fluid-electrolyte status during ECS will be recorded as maternal fluid overload is reported to be associated with respiratory distress in the newborn. (SinghiS,Chookang E;1984) blood loss during and 1 hour after the operation will be estimated.
Maternal data: Patient name, hospital number, age, parity, gestational age, any medical disorder and indication of CS.
Neonatal observations: delivery room care details will be noted, neonatal heart rate, respiratory rate, and signs of respiratory distress— for example, grunting, chest wall retractions, nasal flaring— will be recorded hourly in the postnatal ward for eight hours and once only at 24 hours of age after delivery. Management of a neonate with respiratory distress (defined as respiratory rate at rest.60/min and/or signs of respiratory distress) will be left to the neonatal team. Severity of illness, provisional and final diagnosis, and outcome (death/discharge home/transfer to other hospital) will be recorded if any neonate would be admitted to the neonatal intensive care unit for respiratory distress.
Päivämäärät
| Viimeksi vahvistettu: | 07/31/2017 |
| Ensimmäinen lähetys: | 07/29/2017 |
| Arvioitu ilmoittautuminen lähetetty: | 07/31/2017 |
| Ensimmäinen lähetetty: | 08/03/2017 |
| Viimeisin päivitys lähetetty: | 01/03/2018 |
| Viimeisin päivitys lähetetty: | 01/07/2018 |
| Todellinen opintojen alkamispäivä: | 05/31/2016 |
| Arvioitu ensisijainen valmistumispäivä: | 12/31/2017 |
| Arvioitu tutkimuksen valmistumispäivä: | 12/31/2017 |
Ehto tai tauti
Interventio / hoito
Drug: study group
Vaihe
Varren ryhmät
| Varsi | Interventio / hoito |
|---|---|
| Experimental: study group For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS | Drug: study group |
| No Intervention: control group For the control group mothers enrolled will receive nothing. |
Kelpoisuusehdot
| Sukupuolet, jotka ovat kelpoisia tutkimukseen | Female |
| Hyväksyy terveelliset vapaaehtoiset | Joo |
| Kriteeri | Inclusion Criteria: All pregnant women who are planned for elective (planned& pre labor) cesarean section at 34 -37 weeks gestation. Exclusion Criteria: 1. Pregnancies with known fetal malformation/s or chromosomal aberrations. 2. Presence of absolute contraindication for use of misoprostol.(i.e known hypersensitivity to the drug) 3. Women before 34 and after 37 weeks gestation . 4. Non reassuring cardiotocogram immediately before recruitment. 5. multiple pregnancies. |
Tulokset
Ensisijaiset tulosmittaukset
1. 1- Rate of Neonatal Intensive Care Unit admission for neonatal respiratory distress. [During the first 24 hours of life.]
